Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study-Reference-Cited by-同舟云学术

Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study

Published:2018-05-16 Issue:5 Volume:6 Page:74-83
ISSN:2307-8960
Container-title:World Journal of Clinical Cases
language:
Short-container-title:WJCC

Author:

Lei Xue-Fen,Ke Yang,Bao Tian-Hao,Tang Hao-Ran,Wu Xue-Song,Shi Zhi-Tian,Lin Jie,Zhang Zhi-Xian,Gu Hou,Wang Lin

Publisher

Baishideng Publishing Group Inc.

Subject

General Medicine

Reference52 articles.

1. Global cancer statistics, 2012

2. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis

3. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion

4. Recent advances in multidisciplinary management of hepatocellular carcinoma

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis;Frontiers in Oncology;2023-05-17

2. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis;World Journal of Surgical Oncology;2023-03-31

3. Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study;Clinical Medicine Insights: Oncology;2023-01

4. Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis;Cancers;2022-07-29

5. Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current;Oncology Letters;2021-09-23